Formycon Concludes Successful Development Of Stelara Biosimilar Ahead Of Annual Results
Firm Anticipates Significant Revenue Contributions Starting 2023
Formycon has successfully concluded the development of its ustekinumab biosimilar FYB202, with regulatory submissions planned for Q3. It is just one of many biosimilar candidates which the German firm expects to soon start making significant revenue contributions.
